TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27515162

Group type: EXPERIMENTAL
Intervention: Day 1 phase angle measurement at ICU admission
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Day 1 phase angle
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: APACHE II score
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Surgical patient status
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Admission for other diagnosis
Number of subjects: 931

Group type: EXPERIMENTAL
Intervention: Multivariable combined score
Number of subjects: 931
Study: 27515173

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI) and self-determination theory (SDT) based intervention over 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 27515248

Group type: EXPERIMENTAL
Intervention: Low-dose humanized anti-CD20 antibody, veltuzumab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 50
Study: 27515247

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome prevalence
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Age-specific cumulative prevalence
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Components of metabolic syndrome
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Risk factors for metabolic syndrome
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Patterns of metabolic abnormalities
Number of subjects: 650
Study: 27515250

Group type: EXPERIMENTAL
Intervention: Imatinib plus steroids as induction
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Imatinib plus chemotherapy during consolidation
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Imatinib induction with a more than 1.3 log-reduction of BCR-ABL1 levels
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall survival and disease-free survival at 60 months
Number of subjects: 51
Study: 27515308

Group type: EXPERIMENTAL
Intervention: AMSCs grown in human platelet lysate (hPL)
Number of subjects: 15
Study: 27515583

Group type: EXPERIMENTAL
Intervention: ArmeoSenso (IMU-based virtual reality system)
Number of subjects: 11
Study: 27516088

Group type: EXPERIMENTAL
Intervention: Indacaterol/Glycopyrronium (IND/GLY)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol/Fluticasone combination (SFC)
Number of subjects: 0
Study: 27516462

Group type: COMPARATOR
Intervention: No early recurrences (ER) of atrial tachyarrhythmia
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Early recurrences (ER) during the first month post ablation
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Early recurrences (ER) during the second month post ablation
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Early recurrences (ER) during the third month post ablation
Number of subjects: 401
Study: 27516747

Group type: EXPERIMENTAL
Intervention: Smartphone-based micro-interventions (techniques: viscerosensory attention, emotional imagery, facial expression, contemplative repetition)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Smartphone-based micro-interventions
Number of subjects: 27
Study: 27519353

Group type: EXPERIMENTAL
Intervention: HIPEC
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control
Number of subjects: 22
Study: 27519448

Group type: EXPERIMENTAL
Intervention: Duodenal mucosal resurfacing (DMR)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 39
Study: 27519585

Group type: EXPERIMENTAL
Intervention: Margin-directed neoadjuvant radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigator GTV volumes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modelled toxicity risk (NTCP)
Number of subjects: 0
Study: 27520560

Group type: EXPERIMENTAL
Intervention: Molecular subtypes of PDAC
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: HNF1A/B expression levels
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Regulatory network analysis
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Transcription factors (TFs)
Number of subjects: 118
Study: 27520860

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 27520989

Group type: EXPERIMENTAL
Intervention: ivabradine 5 mg twice daily (adjusted to 7.5 mg twice daily if HR >60 bpm)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Standard medical therapy (control group)
Number of subjects: 70
Study: 27521361

Group type: EXPERIMENTAL
Intervention: HCV-viremic PWID
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Cessation of injection drug use
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: HCV-viremic individuals who previously were PWID
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Former injection drug users who are HCV aviremic
Number of subjects: 4

Group type: COMPARATOR
Intervention: Healthy volunteers
Number of subjects: 4
Study: 27521362

Group type: EXPERIMENTAL
Intervention: Chimera 1 (100 PFU)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chimera 2 (100 PFU and 1000 PFU)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chimera 3
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Chimera 4 (10 PFU, 100 PFU, and 1000 PFU)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: All seroconverters
Number of subjects: 36
Study: 27522076

Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) centered on parietal regions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of configural face differences
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Detection of featural face differences
Number of subjects: 0
Study: 27522379

Group type: EXPERIMENTAL
Intervention: Screening procedure (PEFR <80% of predicted and RHSQ >19.5 points)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Two-month health status in patients with undiagnosed COPD
Number of subjects: 169
Study: 27522472

Group type: EXPERIMENTAL
Intervention: Automated EHR extraction
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Medicaid claims
Number of subjects: 150
Study: 27524654

Group type: EXPERIMENTAL
Intervention: Selenoprotein P (SeP) in overweight/obese individuals
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: SEPP1 mRNA expression in subcutaneous adipose tissue
Number of subjects: 63
Study: 27524739

Group type: EXPERIMENTAL
Intervention: Higher plasma leptin levels (quartiles)
Number of subjects: 1601
Study: 27525031

Group type: EXPERIMENTAL
Intervention: Modified Atkins diet (20 to 40 g of carbohydrates daily)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Modified Atkins diet
Number of subjects: 17
Study: 27525046

Group type: EXPERIMENTAL
Intervention: Dietary treatment with extensively hydrolyzed casein formula containing Lactobacillus rhamnosus GG (group 2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Other formulas (group 3)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Healthy controls (group 4)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Active IgE-mediated CMA (group 1)
Number of subjects: 40
Study: 27525190

Group type: EXPERIMENTAL
Intervention: T3D-959 (1.0 mg/kg/day)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control (normal saline)
Number of subjects: 2
Study: 27525313

Group type: EXPERIMENTAL
Intervention: EPI-506
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: galeterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: AR LBD-targeted therapies
Number of subjects: 0
Study: 27525540

Group type: EXPERIMENTAL
Intervention: Exenatide QW 2 mg
Number of subjects: 295
Study: 27526051

Group type: EXPERIMENTAL
Intervention: Ab interno trabecular bypass surgery with Trabectome
Number of subjects: 19

Group type: COMPARATOR
Intervention: Conventional medical, laser, or surgical treatment
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Trabectome surgery with concomitant phacoemulsification
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Trabectome surgery without concomitant phacoemulsification
Number of subjects: 19
Study: 27526059

Group type: EXPERIMENTAL
Intervention: Amino acid-based formula for 12 weeks
Number of subjects: 30
Study: 27526372

Group type: EXPERIMENTAL
Intervention: Cardiac implantable electronic devices (CIED) implantation including 6 pacemakers (PM) and 6 cardiac resynchronization devices (CRT), 2 of which were defibrillators (CRT-D)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: CIED implantation
Number of subjects: 9
Study: 27527001

Group type: EXPERIMENTAL
Intervention: Estradiol
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Leptin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: SHBG
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Estradiol and leptin ratio
Number of subjects: 17
Study: 27527831

Group type: EXPERIMENTAL
Intervention: Helping Babies Breathe (HBB) training
Number of subjects: 70704

Group type: COMPARATOR
Intervention: Control (pre-implementation period)
Number of subjects: 70704
Study: 27528114

Group type: EXPERIMENTAL
Intervention: Active treatment course for CRPC patients
Number of subjects: 0
Study: 27528460

Group type: EXPERIMENTAL
Intervention: Cortisol levels in PMD patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cortisol, clinical symptoms, and genetic variation (NR3C1 and NR3C2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NR3C1 genetic variation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NR3C2 genetic variation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive performance
Number of subjects: 0
Study: 27528526

Group type: EXPERIMENTAL
Intervention: Group-based coaching
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phone-based coaching
Number of subjects: 0
Study: 27528724

Group type: EXPERIMENTAL
Intervention: AM0010 (Pegylated Recombinant Human Interleukin-10) at doses of 1 to 40 μg/kg once per day, self-administered subcutaneously.
Number of subjects: 51
Study: 27529227

Group type: EXPERIMENTAL
Intervention: DIoB assay for immunophenotyping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: DIoB assay for immune monitoring
Number of subjects: 0
Study: 27529295

Group type: EXPERIMENTAL
Intervention: PCOS group
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Trunk fat, waist, and BMI
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: Whole body DXA scan
Number of subjects: 277

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 277
Study: 27530401

Group type: EXPERIMENTAL
Intervention: Qualitative data collection through interviews and focus groups
Number of subjects: 2099

Group type: EXPERIMENTAL
Intervention: Financial insecurity
Number of subjects: 2099
Study: 27530413

Group type: EXPERIMENTAL
Intervention: Primary reconstruction
Number of subjects: 552

Group type: COMPARATOR
Intervention: Revision reconstruction
Number of subjects: 552
Study: 27530528

Group type: EXPERIMENTAL
Intervention: Quarterly postal and online antibiotic prescription feedback over 24 months
Number of subjects: 2900

Group type: COMPARATOR
Intervention: No information provided
Number of subjects: 2900
Study: 27530601

Group type: EXPERIMENTAL
Intervention: pREset stent retriever
Number of subjects: 100

Group type: COMPARATOR
Intervention: Directly Admitted Patients (DAP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transferred Patients (TP)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Transfer status
Number of subjects: 100

Group type: COMPARATOR
Intervention: Occlusion time
Number of subjects: 100
Study: 27530735

Group type: EXPERIMENTAL
Intervention: Motor Function Measure
Number of subjects: 0
Study: 27530939

Group type: EXPERIMENTAL
Intervention: Northern hospitals
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Eastern hospitals
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Tertiary hospitals
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Provincial-level hospitals
Number of subjects: 115
Study: 27531181

Group type: EXPERIMENTAL
Intervention: Aripiprazole once-monthly 400 mg
Number of subjects: 0
Study: 27531346

Group type: EXPERIMENTAL
Intervention: Sustained Atrial Fibrillation
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Paroxysmal Atrial Fibrillation
Number of subjects: 1192
Study: 27531525

Group type: EXPERIMENTAL
Intervention: Bosutinib
Number of subjects: 0
Study: 27531554

Group type: EXPERIMENTAL
Intervention: Primary tumor
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Circulating tumor cells (CTCs)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Circulating free DNA (cfDNA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Liquid biopsy
Number of subjects: 41
Study: 27531679

Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide (25 mg/day orally on days 1-21 of each cycle) and dexamethasone (40 mg/week)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Daratumumab plus lenalidomide/dexamethasone
Number of subjects: 45
Study: 27531735

Group type: EXPERIMENTAL
Intervention: Intimate Partner Violence (IPV)
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Substance use, depression, psychological distress
Number of subjects: 623

Group type: EXPERIMENTAL
Intervention: Discussion of pregnancy intentions
Number of subjects: 623
Study: 27532019

Group type: EXPERIMENTAL
Intervention: Vemurafenib (VEM) 960 mg twice daily for 6 weeks followed by Ipilimumab (IPI) 10 mg/kg every 3 weeks for 4 doses (induction), then every 12 weeks (maintenance) until disease progression or unacceptable toxicity
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vemurafenib (VEM) at previously tolerated dose after progression on IPI
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Vemurafenib (VEM) followed by Ipilimumab (IPI)
Number of subjects: 46
Study: 27532020

Group type: EXPERIMENTAL
Intervention: Hypofractionated chemoradiation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard fractionated chemoradiation
Number of subjects: 0
Study: 27532363

Group type: EXPERIMENTAL
Intervention: HHHFNC at 4 to 6 L/min
Number of subjects: 316

Group type: COMPARATOR
Intervention: nCPAP/BiPAP at 4 to 6 cm H2O
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: HHHFNC
Number of subjects: 316

Group type: COMPARATOR
Intervention: nCPAP/BiPAP
Number of subjects: 316
Study: 27532364

Group type: EXPERIMENTAL
Intervention: Exemestane (25 mg oral daily) plus Everolimus (10 mg oral daily)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Exemestane (25 mg oral daily) plus Placebo
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Exemestane plus Everolimus
Number of subjects: 541
Study: 27533787

Group type: EXPERIMENTAL
Intervention: Tedizolid (200 mg once daily for 6 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Linezolid (600 mg twice daily for 10 days)
Number of subjects: 0
Study: 27533991

Group type: EXPERIMENTAL
Intervention: Coronary Angiography (CA)
Number of subjects: 783

Group type: COMPARATOR
Intervention: No Coronary Angiography (CA)
Number of subjects: 783
Study: 27534260

Group type: EXPERIMENTAL
Intervention: 48-hour sensor glucose concentrations in free-living conditions
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Median sensor glucose concentration
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Correlation with fasting plasma glucose concentrations
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Correlation with serum insulin concentrations
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Correlation with HOMA-IR
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Hyperglycaemic area under the curve (AUC)
Number of subjects: 111
Study: 27534643

Group type: EXPERIMENTAL
Intervention: Serum cysteine
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Serum cysteinylglycine
Number of subjects: 508

Group type: COMPARATOR
Intervention: Cysteine and cysteinylglycine
Number of subjects: 508
Study: 27535544

Group type: EXPERIMENTAL
Intervention: Comprehensive data base of high quality clinical and molecular data
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: In-depth molecular characterization
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Daily assessments and long-term follow-up
Number of subjects: 3000
Study: 27535663

Group type: EXPERIMENTAL
Intervention: Plerixafor 240 μg/kg administered subcutaneously every other day from day +2 until day +21 or until neutrophil recovery
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (95 allogeneic peripheral blood stem cell transplant recipients)
Number of subjects: 30
Study: 27535748

Group type: EXPERIMENTAL
Intervention: Evofosfamide (120 mg/m2 to 340 mg/m2) administered one week before chemoradiotherapy and repeated weekly up to six doses.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evofosfamide in combination with neo-adjuvant chemoradiotherapy.
Number of subjects: 0
Study: 27535872

Group type: EXPERIMENTAL
Intervention: High education
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 100
Study: 27536380

Group type: EXPERIMENTAL
Intervention: PATE (Parents as Teachers curriculum enhanced with a nutrition and lifestyle behavior curriculum)
Number of subjects: 82

Group type: COMPARATOR
Intervention: PAT (Parents as Teachers curriculum only)
Number of subjects: 82
Study: 27536421

Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (A/V) 10/160 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Losartan/hydrochlorothiazide (L/H) 100/25 mg
Number of subjects: 90
Study: 27536422

Group type: EXPERIMENTAL
Intervention: Rosiglitazone for 52 weeks
Number of subjects: 226

Group type: COMPARATOR
Intervention: Metformin for 52 weeks (active control)
Number of subjects: 226
Study: 27536431

Group type: EXPERIMENTAL
Intervention: SPC aliskiren 300/amlodipine 10
Number of subjects: 187
Study: 27536436

Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Belimumab (1 mg/kg and 10 mg/kg)
Number of subjects: 12
Study: 27536437

Group type: EXPERIMENTAL
Intervention: Montelukast added to ICS + LABA for 4 weeks
Number of subjects: 17
Study: 27536442

Group type: EXPERIMENTAL
Intervention: Migalastat HCl 50 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Migalastat HCl 150 mg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Migalastat HCl 450 mg
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 27536449

Group type: EXPERIMENTAL
Intervention: Levomilnacipran ER 40-120 mg/day
Number of subjects: 355

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 355
Study: 27536452

Group type: EXPERIMENTAL
Intervention: Levocetirizine oral solution (OS) 5 mg
Number of subjects: 2

Group type: COMPARATOR
Intervention: Cetirizine dry syrup (DS) 10 mg
Number of subjects: 2
Study: 27536459

Group type: EXPERIMENTAL
Intervention: 5 × 0.1 mg dutasteride capsules
Number of subjects: 36

Group type: COMPARATOR
Intervention: 1 × 0.5 mg dutasteride capsule
Number of subjects: 36
Study: 27536708

Group type: EXPERIMENTAL
Intervention: Intrathecal administration of rituximab
Number of subjects: 0
Study: 27536938

Group type: EXPERIMENTAL
Intervention: Sigmoidoscopy
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Circumcision
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Post-procedure abstinence recommendations
Number of subjects: 29
Study: 27537328

Group type: EXPERIMENTAL
Intervention: Experimental diet lower in sodium, protein, and acid precursors, supplemented with water for 4 weeks
Number of subjects: 12
Study: 27537786

Group type: EXPERIMENTAL
Intervention: Deferasirox (up to 40 mg/kg/d)
Number of subjects: 46
Study: 27538197

Group type: EXPERIMENTAL
Intervention: Bronchoarterial (BA) ratio measurement
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Association of BA ratio with lung function
Number of subjects: 106
Study: 27538433

Group type: EXPERIMENTAL
Intervention: Lower-risk MDS (IPSS low and intermediate-1 risk)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Higher-risk MDS (IPSS intermediate-2 and high risk)
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: ICUS
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: AML
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Tissue substudy
Number of subjects: 1500

Group type: EXPERIMENTAL
Intervention: Patient-reported health-related quality of life
Number of subjects: 1500
Study: 27538465

Group type: EXPERIMENTAL
Intervention: Panagen (tablet form of fragmented human DNA preparation)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Panagen
Number of subjects: 80
Study: 27539172

Group type: EXPERIMENTAL
Intervention: Social-business eating pattern
Number of subjects: 4082

Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 4082
Study: 27539301

Group type: EXPERIMENTAL
Intervention: Amyloid-β PET imaging
Number of subjects: 178

Group type: COMPARATOR
Intervention: Cognitively healthy stroke survivors
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: PS-MCI patients
Number of subjects: 178
Study: 27540019

Group type: EXPERIMENTAL
Intervention: High-dose inhaled corticosteroid (ICS) treatment
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Systemic inflammation (elevated IL-6 or hsCRP)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: ≥2 comorbidities
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: High-dose ICS
Number of subjects: 170
Study: 27540363

Group type: EXPERIMENTAL
Intervention: Etravirine 200 mg twice-daily
Number of subjects: 15
Study: 27540466

Group type: EXPERIMENTAL
Intervention: Omalizumab 300 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27541029

Group type: EXPERIMENTAL
Intervention: Perioperative diagnosis by the surgeon
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Postoperative antibiotics
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Histological confirmation of appendicitis
Number of subjects: 131
Study: 27541373

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 454

Group type: COMPARATOR
Intervention: Control
Number of subjects: 454
Study: 27541380

Group type: EXPERIMENTAL
Intervention: Rosuvastatin (20 mg/day)
Number of subjects: 122
Study: 27542133

Group type: EXPERIMENTAL
Intervention: Fecal Microbial Transplantation (FMT) from healthy donors
Number of subjects: 19
Study: 27542325

Group type: EXPERIMENTAL
Intervention: bant2 mobile app intervention in addition to standard of care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Current standard of care
Number of subjects: 150